| Literature DB >> 27859753 |
J M Sargeant1,2, A M O'Connor3, I R Dohoo4, H N Erb5, M Cevallos6, M Egger6, A K Ersbøll7, S W Martin2, L R Nielsen8, D L Pearl2, D U Pfeiffer9, J Sanchez10, M E Torrence11, H Vigre12, C Waldner13, M P Ward14.
Abstract
BACKGROUND: Reporting of observational studies in veterinary research presents challenges that often are not addressed in published reporting guidelines.Entities:
Keywords: Animal Health; Animal Reporting guidelines; Animal welfare; Food Safety; Observational studies; Production
Mesh:
Year: 2016 PMID: 27859753 PMCID: PMC5115188 DOI: 10.1111/jvim.14574
Source DB: PubMed Journal: J Vet Intern Med ISSN: 0891-6640 Impact factor: 3.333
Modifications to the original STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement checklist for the STROBE‐Vet statement
| Item | STROBE Recommendation | STROBE‐Vet Recommendation | |
|---|---|---|---|
| Title and Abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | (a) |
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found | (b) | ||
| Introduction | |||
| Background/Rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Explain the scientific background and rationale for the investigation being reported |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | (a) State specific objectives, including any |
| (b) | |||
| Methods | |||
| Study design | 4 | Present key elements of study design early in the paper | Present key elements of study design early in the paper |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow‐up, and data collection | (a) Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow‐up, and data collection |
| (b) If applicable, | |||
| Participants | 6 |
(a) | (a) |
|
(b) | (b) | ||
| (c) | |||
|
| |||
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | (a) Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. If applicable, give diagnostic criteria |
| (b) | |||
| (c) | |||
| Data sources/measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | (a) For each variable of interest, give sources of data and details of methods of assessment (measurement). If applicable, describe comparability of assessment methods |
| (b) | |||
| (c) | |||
| (d) | |||
| Bias | 9 | Describe any efforts to address potential sources of bias | Describe any efforts to address potential sources of bias |
| Study size | 10 | Describe how the study size was arrived at | (a) Describe how the study size was arrived at |
| (b) | |||
| (c) | |||
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | (a) Describe all statistical methods |
| (b) Describe any methods used to examine subgroups and interactions | (b) | ||
| (c) Explain how missing data were addressed | (c) Explain how missing data were addressed | ||
|
( | (d) If applicable, | ||
| ( | (e) | ||
| Results | |||
| Participants | 13 | (a) Report the numbers of individuals at each stage of study—e.g, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow‐up, and analyzed | (a) Report the numbers of |
| (b) Give reasons for non‐participation at each stage | (b) Give reasons for non‐participation at each stage | ||
| (c) Consider use of a flow diagram | (c) Consider use of a flow diagram, | ||
| Descriptive data on exposures and potential confounders | 14 | (a) Give characteristics of study participants (e.g, demographic, clinical, social) and information on exposures and potential confounders | (a) Give characteristics of study participants (e.g, demographic, clinical, social) and information on exposures and potential confounders |
| (b) Indicate number of participants with missing data for each variable of interest | (b) Indicate number of participants with missing data for each variable of interest | ||
| (c) | (c) Summarize follow‐up time (e.g, average and total amount) | ||
| Outcome data | 15 |
| (a) |
|
| (b) | ||
|
| (c) | ||
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder‐adjusted estimates and their precision (e.g, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | (a) Give unadjusted estimates and, if applicable, adjusted estimates and their precision (e.g, 95% confidence interval). Make clear which confounders |
| (b) Report category boundaries when continuous variables were categorized | (b) Report category boundaries when continuous variables were categorized | ||
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | ||
| Other analyses | 17 | Report other analyses done— analyses of subgroups and interactions, and sensitivity analyses | Report other analyses done, |
| Discussion | |||
| Key results | 18 | Summarize key results with reference to study objectives | Summarize key results with reference to study objectives |
| Strengths and Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Discuss |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence |
| Generalizability | 21 | Discuss the generalizability (external validity) of the study results | Discuss the generalizability (external validity) of the study results |
| Other Information | |||
|
| 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | (a) |
Underlined text represents modifications or additions to the original STROBE wording.
Level of organization recognizes that observational studies in veterinary research often deal with repeated measures (within an animal or herd) or animals that are maintained in groups (such as pens and herds); thus, the observations are not statistically independent. This non‐independence has profound implications for the design, analysis, and results of these studies.
The word “participant” is used in the STROBE statement. However, for the veterinary version, it is understood that “participant” should be addressed for both the animal owner/manager and for the animals themselves.
Give such information separately for cases and controls in case‐control studies and, if applicable, for exposed and unexposed groups in cohort and cross‐sectional studies.